SharePoint
A- A A+
Home > Research & Education > Clinical Trials > Ongoing Trials

Research & Education

Ongoing Trials

Ongoing Trials

  1. Phase I/II study of expanded, activated autologous natural killer cell infusions with trastuzumab for patients with HER2+ breast and gastric cancer
  2. Phase Ib dose-confirmation study of ASLAN001 combined with weekly paclitaxel and carboplatin in advanced solid tumours, followed by an open-label phase II study in patients with stage I-III HER2 positive breast cancer
  3. Phase Ib followed by Phase II study of pre-operative treatment with lenvatinib combined with letrozole in post-menopausal women with newly diagnosed hormone receptor positive breast cancer patients with measurable primary breast tumor 
  4. Single Arm Phase 2 Study of Metformin and Simvastatin in addition to Fulvestrant in Metastatic Estrogen Receptor Positive Breast Cancer
  5. A Phase II window-of-opportunity study of single agent lenvatinib in estrogen receptor positive early stage breast cancer 
  6. A Randomized, Open-Label, Phase 3 Study of Abemaciclib combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
  7. A Phase III, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of the Efficacy and Safety of Atezolizumab in Combination with Chemotherapy for Patients with Early Relapsing Recurrent (Inoperable Locally Advanced or Metastatic) Triple-Negative Breast Cancer.
  8. A Double-Blind, Placebo-Controlled, Randomized Phase III Study of Ipatasertib in Combination with Paclitaxel as a Treatment for Patients with PIK3CA/AKT1/PTEN-Altered, Locally Advanced ot Metastatic, Triple-Negative Breast Cancer ot Hormone Receptor– Positive, HER2-Negative Breast Cancer
  9. A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Women with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane
  10. Asian, International, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Tamoxifen With or Without Palbociclib ± Goserelin in Women with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer
  11. A Multi-center, open-label, randomized clinical trial comparing the efficacy and safety of the antibody-drug conjugate SYD985 to physician's choice in patients with HER2-positive unresectable locally advanced or metastatic breast 

  1. A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC)

  1. Phase Ib dose-confirmation study of ASLAN001 combined with weekly paclitaxel and carboplatin in advanced solid tumours, followed by an open-label phase II study in patients with stage I-III HER2 positive breast cancer
  2. Phase Ib followed by Phase II study of pre-operative treatment with lenvatinib combined with letrozole in post-menopausal women with newly diagnosed hormone receptor positive breast cancer patients with measurable primary breast tumor 
  3. da VINci study (OTSGC-A24 therapeutic peptide Vaccine + Ipilimumab + Nivolumab) Nivolumab, Ipilimumab and OTSGC-A24 therapeutic peptide vaccine in gastric cancer – a combination immunotherapy Phase Ib study
  4. Phase 1b open label dose assessment study of ASLAN001 (Varlitinib) in patients with advance/ metastatic hepatocellular carcinoma (HCC) with an expansion cohort in HCC patients expressing HER3 who have progressed on first line Sorafenib or Lenvatinib
  5. An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma
  6. Phase I study of low dose whole abdominal radiation therapy (LDWART) in combination with weekly paclitaxel for platinum resistant ovarian cancer with predominant non-visceral abdominal disease
  7. An Investigator Sponsored Phase 1 Study of the Safety, Pharmacokinetics and Pharmacodynamics of Escalating Doses followed by Dose Expansion of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Asian Patients with Advanced or Metastatic Solid Tumor Malignancies
  8. Phase 1, Open Label, Dose Escalation and Cohort Expansion Study of YS-ON-001 in Patients with Advanced Solid Tumors
  9. A First-in-human, Multi-centre, Open-label, Phase 1 Clinical Study With RNA Oligonucleotide Drug MTL-CEBPA To Investigate Its Safety And Tolerability In Patients With Advanced Liver Cancer 
  10. Phase 1b Multi-indication Study of Anetumab Ravtansine (BAY 94-9343) in Patients with Mesothelin Expressing Advanced or Recurrent Malignancies
  11. CPDR001X2103: Phase Ib, open-label, multi-center study to characterize the safety, tolerability and pharmacodynamics (PD) of PDR001 in combination with CJM112, EGF816, Ilaris® (canakinumab) or Mekinist® (trametinib)
  12. An open-label, Phase 1, first-in-human, dose escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and tumor response
  13. profile of the anti-CEACAM6 antibody BAY 1834942 in patients with advanced solid tumors
  14. A multicenter Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and recommended Phase 2 dose (RP2D)of the combination of rogaratinib and copanlisib in patients with FGFR-positive refractory, locally advanced or metastatic solid tumors (ROCOCO)
  15. An Investigator Sponsored Phase I Study of the Safety, Tolerability and Pharmacodynamics of Escalating Doses of combination treatment of AZD5363 + Olaparib + Durvalumab (MEDI4736) in Patients with Advanced or Metastatic Solid Tumor Malignancies                       


  1. Feasibility study of intraperitoneal paclitaxel with standard-of-care oxalipatin and capecitabine in patients with advanced gastric cancer 
  2. A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab in Combination with Oxaliplatin plus Fluoropyrimidine versus Oxaliplatin plus Fluoropyrimidine in Subjects with Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer
  3. A Randomized Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab Combined with Fluorouracil plus Cisplatin versus Fluorouracil plus Cisplatin in Subjects with Unresectable Advanced, Recurrent or Metastatic Previously Untreated Esophageal Squamous Cell Carcinoma
  4. A Phase III, Randomized, Double-Blind, Clinical Trial of Pembrolizumab (MK-3475) plus Chemotherapy (XP or FP) versus Placebo plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Subjects with Gastric and Esophageal Adenocarcinoma  (KEYNOTE-585)
  5. A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects with Resected Esophageal, or Gastroesophageal Junction Cancer
  6. da VINci study (OTSGC-A24 therapeutic peptide Vaccine + Ipilimumab + Nivolumab) Nivolumab, Ipilimumab and OTSGC-A24 therapeutic peptide vaccine in gastric cancer – a combination immunotherapy Phase Ib study                   

  1. Phase I study of low dose whole abdominal radiation therapy (LDWART) in combination with weekly paclitaxel for platinum resistant ovarian cancer with predominant non-visceral abdominal disease
  2. A Multicentre Phase II randomised trial of DURVALUMAB versus physician’s choice chemotherapy in recurrent ovarian clear cell adenocarcinomas (MOCCA)

  1. ​A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (C16021)
  2. A Phase II/III, Randomised, Multicentre Study of MOR00208 with Bendamustine versus Rituximab with Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who Are Not Eligible for High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT) – B-MIND 
  3. A Randomized, Double-Blind Phase 3 Study of Ibrutinib in Combination with Corticosteroids versus Placebo in  Combination with Corticosteroids in Subjects with New Onset Chronic Graft versus Host Disease
  4. Single arm, multicentre study of Carfilzomib in combination with Thalidomide and Dexamethasone (CaTD) in patients with relapsed and/or refractory multiple myeloma (RRMM).
  5. Randomized Phase 3 study of Pomalidomide-Cyclophosphamide-Dexamethasone (PCD) versus Pomalidomide-Dexamethasone (PD) in relapse or refractory myeloma. An AMN study 
  6. A Phase 3, multicenter, randomised, double-blind, double dummy, active controlled study to assess the efficacy and safety of maribavir compared to Valganciclovir for the treatment of cytomegalovirus (CMV) infection in hematopoietic stem cell transplant recipients (SHP620-302)
  7. A Phase III, randomized, double-blind, controlled, multicenter study of intravenous PI3K inhibitor copanlisib in combination with standard immunochemotherapy versus standard immunochemotherapy in patients with relapsed indolent non-Hodgkin’s lymphoma (iNHL) 
  8. A multicenter, randomised, phase III registration trial of transplatation of NICORD, Ex vivo expended, umbilical cord blood-derived, stem and progenitor cells, versus unmanipulated umbilical cord blood for pateints with hematological maglinancies
  9. Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation
  10. A Phase IIA Dose Optimisation Study of ASLAN003 in Acute Myeloid Leukemia (ASLAN003-003)
  11. Phase 2 study of Daratumumab in combination with Thalidomide and Dexamethasone in relapse and / or refractory myeloma
  12. A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease

  1. ​A phase II multicenter, single arm study of oral BGJ398 in adult patients with advanced or metastatic cholangiocarcinoma with FGFR2 gene fusions or other FGFR genetic alterations who failed or are intolerant to platinum-based chemotherapy
  2. A Study of Safety, Tolerability, and Clinical Activity of MEDI4736 and Tremelimumab Administered as Monotherapy and in Combination to Subjects with Unresectable Hepatocellular Carcinoma
  3. Selective Internal Radiation Therapy with Yttrium-90 Resin Microspheres followed by Gemcitabine plus Cisplatin for Intra-hepatic Cholangiocarcinoma: A Phase II study
  4. Phase 1b open label dose assessment study of ASLAN001 (Varlitinib) in patients with advance/ metastatic hepatocellular carcinoma (HCC) with an expansion cohort in HCC patients expressing HER3 who have progressed on first line Sorafenib or Lenvatinib.
  5. A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Varlitinib Plus Capecitabine Versus Placebo Plus Capecitabine In Patients With Advanced or Metastatic Biliary Tract Cancer As Second-Line Systematic Therapy
  6. An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma 
  7. A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab versus Placebo for Participants with Hepatocellular Carcinoma Who Are at High Risk of Recurrence after Curative Hepatic Resection or Ablation
  8. A Pilot Study of Ciprofloxacin plus Gemcitabine and Nab-Paclitaxel Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

  1. A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 In Completely Resected Non-Small Cell Lung Cancer
  2. Phase II Study of AZD9291 in patients with advanced stage non-small cell lung cancer following prior EGFR TKI Therapy with EGFR and T790M mutations detected in plasma circulating tumor DNA
  3. Open-Label, Randomized Trial of Nivolumab (BMS-936558) plus Pemetrexed/Platinum or Nivolumab plus Ipilimumab (BMS-734016) vs Pemetrexed plus Platinum in Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Subjects with Epidermal Growth  Factor Receptor (EGFR) Mutation, T790M Negative Who Failed 1L EGFR Tyrosine Kinase Inhibitor Therapy 
  4. A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: Blood-First Assay Screening Trial)"
  5. An Open-label, Multicenter, Phase II Study to Evaluate the Therapeutic Activity of RO6874281, An Immunocytokine, Consisting of Interleukin-2 Variant (IL-2V) Targeting Fibroblast Activation Protein-A (FAP), in Combination with Atezolizumab (Anti-PD-L1), Administered Intravenously, in Participants with Advanced and/or Metastatic Solid Tumors

  1. Reactivating NK cells in treating refractory head and neck cancer 
  2. Dendritic cell therapy with CD137L-DC-EBV-VAX in locally advanced stage IV or locally recurrent/metastatic Nasopharyngeal Carcinoma
  3. A Phase II Trial of Ipilimumab in combination with Nivolumab in Patients with Advanced Nasopharyngeal Carcinoma


  1. Prospective study of UDP-gluconoryltransferase (UGT) 2B17 genotype as a predictive marker of exemestane pharmacokinetics and pharmacodynamics in Asian women with hormone receptor-positive advanced breast cancer
  2. An Investigator Sponsored Phase 1 Study of the Safety, Pharmacokinetics and Pharmacodynamics of Escalating Doses followed by Dose Expansion of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Asian Patients with Advanced or Metastatic Solid Tumor Malignancies
  3. A Phase 1A/B Study to Evaluate the Safety and Tolerability of ETC-1922159 in Advanced Solid Tumours
  4. STARTRK-2: An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements 
  5. Phase II trial of cisplatin combined with oral TS-1 in patients with advanced solid tumors with different degrees of liver dysfunction
  6. Phase 1, Open Label, Dose Escalation and Cohort Expansion Study of YS-ON-001 in Patientswith Advanced Solid Tumors
  7. A First-in-human, Multi-centre, Open-label, Phase 1 Clinical Study With RNA Oligonucleotide Drug MTL-CEBPA To Investigate Its Safety And Tolerability In Patients With Advanced Liver Cancer 
  8. Phase IIa Dose-Expansion and Biomarker Study of OPB-111077 in An Enriched Population of Treatment-Refractory Advanced Solid Tumors
  9. Phase 1b Multi-indication Study of Anetumab Ravtansine (BAY 94-9343) in Patients with Mesothelin Expressing Advanced or Recurrent Malignancies
  10. An open-label, first-in-human, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose and / or recommended Phase II dose of the ATR inhibitor BAY 1895344 in patients with advanced solid tumors and Lymphomas 
  11. CPDR001X2103: Phase Ib, open-label, multi-center study to characterize the safety, tolerability and pharmacodynamics (PD) of PDR001 in combination with CJM112, EGF816, Ilaris® (canakinumab) or Mekinist® (trametinib)
  12. An open-label, Phase 1, first-in-human, dose escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and tumor response profile of the anti-CEACAM6 antibody BAY 1834942 in patients with advanced solid tumors
  13. A multicenter Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and recommended Phase 2 dose (RP2D)of the combination of rogaratinib and copanlisib in patients with FGFR-positive refractory, locally advanced or metastatic solid tumors (ROCOCO)
  14. An Investigator Sponsored Phase I Study of the Safety, Tolerability and Pharmacodynamics of Escalating Doses of combination treatment of AZD5363 + Olaparib + Durvalumab (MEDI4736) in Patients with Advanced or Metastatic Solid Tumor Malignancies                        
  15. A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)